AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIa randomized, double-blind, placebo-controlled study. The study objective
is to investigate the efficacy and safety of repeat oral dosing of the investigational
medicinal product (IMP) AP-325 for the treatment of peripheral post-surgical neuropathic pain
(PPNP) after breast surgery (breast cancer interventions), chest surgery (i.e. thoracotomy,
video assisted thoracoscopy and sternotomy) or groin hernia repair (i.e. femoral hernia
repairs and inguinal hernia repairs).